Efficacy and safety of veliparib in the treatment of advanced/metastatic breast cancer: a meta-analysis of phase II and III randomized controlled trials-Reference-Cited by-同舟云学术

Efficacy and safety of veliparib in the treatment of advanced/metastatic breast cancer: a meta-analysis of phase II and III randomized controlled trials

Published:2023-11-17 Issue: Volume: Page:1-8
ISSN:1120-009X
Container-title:Journal of Chemotherapy
language:en
Short-container-title:Journal of Chemotherapy

Author:

Sun Wenxia¹,Li Jing²^ORCID

Affiliation:

1. Engineering Research Center for Pharmaceuticals and Equipment of Sichuan Province, Chengdu University, Chengdu, Sichuan, P.R.China

2. College of Pharmacy, Southwest Minzu University, Chengdu, Sichuan, P.R.China

Publisher

Informa UK Limited

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/1120009X.2023.2281760

Reference30 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial

3. PARP and PARG inhibitors in cancer treatment

4. An update on PARP inhibitors—moving to the adjuvant setting

5. Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurobehavioral functions during recurrent periods of sleep restriction: effects of intra-individual variability in sleep duration;SLEEP;2024-01-14